Cargando…
Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort
PURPOSE: We developed the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer (KPCRC-HG) that predicts the probability of prostate cancer (PC) of Gleason score 7 or higher at the initial prostate biopsy in a Korean cohort (http://acl.snu.ac.kr/PCRC/RISC/). In addition, KPCRC-HG was...
Autores principales: | Park, Jae Young, Yoon, Sungroh, Park, Man Sik, Choi, Hoon, Bae, Jae Hyun, Moon, Du Geon, Hong, Sung Kyu, Lee, Sang Eun, Park, Chanwang, Byun, Seok-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207506/ https://www.ncbi.nlm.nih.gov/pubmed/28046017 http://dx.doi.org/10.1371/journal.pone.0168917 |
Ejemplares similares
-
Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort
Publicado: (2017) -
Initial Biopsy Outcome Prediction in Korean Patients-Comparison of a Noble Web-based Korean Prostate Cancer Risk Calculator versus Prostate-specific Antigen Testing
por: Park, Jae Young, et al.
Publicado: (2011) -
Can Western Based Online Prostate Cancer Risk Calculators Be Used to Predict Prostate Cancer after Prostate Biopsy for the Korean Population?
por: Lee, Dong Hoon, et al.
Publicado: (2013) -
Mobile Application-Based Seoul National University Prostate Cancer Risk Calculator: Development, Validation, and Comparative Analysis with Two Western Risk Calculators in Korean Men
por: Jeong, Chang Wook, et al.
Publicado: (2014) -
External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)